MedTrace Logo

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

NCT05431543 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2024-09-05

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.

Conditions

Interventions

DRUG

Aceclidine+Brimonidine combination ophthalmic solution

LNZ101-combination ophthalmic solution

DRUG

Aceclidine ophthalmic solution

LNZ100- aceclidine ophthalmic solution

DRUG

Vehicle proprietary ophthalmic solution

Proprietary Vehicle ophthalmic solution

Sponsors & Collaborators

  • LENZ Therapeutics, Inc

    lead OTHER

Principal Investigators

  • Alisyn Facemire, BA · LENZ Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-06
Primary Completion
2022-12-14
Completion
2022-12-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05431543 on ClinicalTrials.gov